Nephros, Inc. : Defining the Future of ESRD Therapy

Industry Meetings

News:
July 14, 2008 Nephros Exhibiting at Maryland ASHE Conference July 20-23, 2008 Click here for additional information
June 5, 2008 Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products Click here for additional information
June 2, 2008 Nephros exhibiting at Denver, Colorado APIC Conference June 15-19, 2008 Click here for additional information
May 10, 2008 Nephros to Exhibit at the XLV ERA-EDTA Congress in Stockholm, Sweden, May 10-13, 2008 Click here for additional information
October 16, 2007 Nephros Initiates Pivotal U.S. Trial for OLpur™ H2H™ Hemodiafiltration Module and OLpur™ MD 220 Hemodiafilter Click here for additional information
October 3, 2007 Nephros Receives Non-Compliance Notification from Amex Click here for additional information
September 25, 2007 Nephros Raises $12.7 Million in New Financing Click here for additional information
August 13, 2007 Nephros Reports Second Quarter 2007 Financial Results Revenues Increase 15%, Net Loss is Reduced Click here for additional information
August 7, 2007 Nephros Discloses Nonpayment of Installment under the Lancer Settlement Agreement in Current Report on Form 8-K Click here for additional information
July 20, 2007 Nephros Names New Independent Auditing Firm Click here for additional information
May 23, 2007 Nephros Reports Departure of Director Click here for additional information
May 16, 2007 Nephros to Initiate U.S. Clinical Trials Click here for additional information
May 15, 2007 Nephros Reports First Quarter 2007 Financial Results Revenues Increase 70%, Net Loss is Reduced Click here for additional information
May 3, 2007 Nephros Provides Information Regarding Auditor's Going Concern Report and Fiscal 2006 Results Click here for additional information
May 1, 2007 Nephros Reports Departure of Director Click here for additional information
March 1, 2007 Nephros Completes Informational Request from the FDA on Investigational Device Exemption Application Nephros MD and H2H Technologies Clinical Trials Expected to Commence in March 2007 Click here for additional information
January 29, 2007 Nephros Receives Conditional Approval from the FDA of Investigational Device Exemption Application Nephros MD and H2H Technologies Targeted to Begin Clinical Trials in First Quarter 2007 Click here for additional information
more news >>
Nephros can be found on the American Stock Exchange under the ticker symbol NEP. Click here for additional information.

Dialysis Industry meetings:

Nov 4 - Nov 9, 2008
American Society of Nephrology ASN
Philadelphia, PA

Water Industry Meetings:

Oct 22 - 25, 2008
American Society of Healthcare Risk Management
Denver, CO

Jul 20 - Jul 23, 2008
American Society of Healthcare Engineering (ASHE) of the American Hospital Association (AHA)
Washington, DC / Booth #839
Jun 15 - Jun 19, 2008
APIC 2008
Denver, CO

Nephros introduces new
Dual Stage Water Ultrafilter

The Future of ESRD Therapy
Nephros, Inc. has developed new system technologies and companion products that will improve survival, increase the quality of life, and reduce medical costs for patients with End Stage Renal Disease (ESRD). The Company has developed unique and proprietary technologies that address the major overriding needs of ESRD treatment by providing:

Significant improvement in treatment efficacy, particularly with respect to the removal of many harmful substances, such as the "middle molecule" beta-2-microglobulin, not effectively removed by current dialytic methods.

Cost effective therapies that provide a better life for the patient while meeting the business needs of the clinic.